THE UNITED STATES PATENT AND TRADEMARK OFFICE

ation of:

Serial No.: 08/083,590

NUCLEIC ACIDS

Attorney Docket No.: 7326-015

Filed: June 25, 1993

RECEIVED Artavanis-Tsakonas et al.

AUG 0 5 1993

APPLICATION DIVISION

Examiner:

Group Art Uni

Huy 1 5 1993

いいい いっしょう

Pennie & Edmonds

1155 Avenue of the Americas New York, New York 10036-2711

SUPPLEMENTAL INFORMATION **DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56**

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

THERAPEUTIC AND DIAGNOSTIC

METHODS AND COMPOSITIONS BASED ON NOTCH PROTEINS AND

SIR:

For:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent Office of all references coming to the attention of Applicants or attorneys or agents for Applicants which are or may be material to the patentability of any claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the references listed on the attached revised form PTO 1449, copies of which are enclosed.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art"

| | • |
|---|--|
| | |
| | |
| EXP | RESS MAIL CERTIFICATION |
| "Express Mail" label No. TB 389 223 142 US | Date of Deposit July 28, 1993 |
| nereby certify that this paper or fee is being deposited with | the United States Postal Service "Express Mail Post Office to Addressee" service under to the Commissioner of Patents and Trademarks, Washington, D.C. 20231. |
| | FRANK DIANGELIS |
| | Service of the servic |
| | PENY-19304 |

against the subject application. Consequently, Applicants respectfully dealine to use form PTO-1449, since this form identifies all of the references cited therein as "Prior Art." As an alternative, Applicants submit herewith several pages of a "revised form PTO 1449" entitled "List of References Cited" instead of "List of Prior Art Cited."

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed within three months of the date of filing of the above-identified application or before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Pennie & Edmonds deposit account no. 16-1150; a duplicate of this sheet is enclosed.

Respectfully submitted,

Date: July 28, 1993

Leslie Misrock (Reg. No.)

PENNIE & EDMONDS 1155 Avenue of the Americas New York, New York 10036-2711

(212) 790-9090